Logo

Exelixis, Genomica Merger Finally Gets Stock-Exchange Ratio

Dec 26, 2001

SAN FRANCISCO, Dec. 26 - The proposed Genomica-Exelixis merger finally got its stock-exchange ratio. The ratio for converting shares of Genomica stock into shares of Exelixis stock will be 0.28306, the companies said on Wednesday .

 

The initial offering period for the exchange will expire midnight Eastern Standard Time on Dec. 28.

 

Exelixis announced on Nov. 19 plans to acquire Genomica in a stock deal valued at $110 million, and Genomica's board of directors unanimously recommended that the firm's stockholders accept the offer, according to the company.

Breaking News
The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.